The Role of PARPi in Prostate Cancer: Experts Knowledge Share
The Role of PARPi in Prostate Cancer: Experts Knowledge Share
Prof. Emmanuel S. Antonarakis, Dr. Neal D. Shore, Prof. Andrew J. Armstrong
Prof. Emmanuel S. Antonarakis
Medical Oncologist
Johns Hopkins Medicine
United States (US)
Dr. Neal D. Shore
Urologist
Carolina Urologic Research Centre and GenesisCare
United States (US)
Prof. Andrew J. Armstrong
Medical Oncologist
Duke University School of Medicine
United States (US)
| 
5 min
|
Aug 2020
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
On August 26th and August 28th 2020, two Experts Knowledge Share interactive webinars connected global participants with renowned panel experts to discuss the therapeutic role of PARP inhibitors in prostate cancer. Panellists included Dr. Neal D. Shore (Programme Chair), Prof. Andrew J. Armstrong, and Prof. Emmanuel S. Antonarakis.
Key topics included:
-
Prevalence of DDR mutations in prostate cancer, and somatic and germline testing
-
PARPi mechanism of action
-
Recent clinical trial data and ongoing studies
-
Efficacy and safety profiles of PARPi
-
Patient case studies
In this video, Dr. Neal D. Shore summarises this Experts Knowledge Share programme and the expanding role for PARP inhibitors in prostate cancer therapy. Follow the link above to access the accredited e-learning associated with the programme.
Other programmes of interest
0 min
Other programmes developed by Dr. Neal D. Shore
Dr. Neal D. Shore
Urologist
Carolina Urologic Research Centre and GenesisCare
United States (US)
